Objective: Disease-Modifying Treatments (DMTs) have contributed to a new clinical landscape for people with relapsing-remitting multiple sclerosis (pwRRMS). A challenge for services is how to support DMT decisions with changing clinical evidence, and differing treatment goals. This article investigates how pwRRMS weigh up the pros and cons of DMTs by examining how communication at the point of diagnosis is related to DMT decisions.
Methods: 30 semi-structured interviews with pwRRMS in England were conducted using a theoretical purposive sampling strategy and analysed using the thematic approach to answer: How does communication about RRMS during diagnosis influence decisions about when and which DMT to choose?
Results: Three meta-themes were identified: a) communication context; b) delayed communication and hope for people with "non-active" RRMS at diagnosis; c) people with "active" RRMS at diagnosis: Conflated, generic, selective and simplified information CONCLUSION: At the time of diagnosis, patient-physician interactions are characterised by emotions and information complexity. Clinical, social and psychological DMT filtering mechanisms are activated during first decisions. Personalised evidence is needed to make informed decisions.
Practice Implications: Patient decision aids should consider first and consecutive decisions and should not encourage a false sense of large choices that could add to decision anxiety.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pec.2020.05.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of Baseline Lipopolysaccharide-Binding Protein with Expanded Disability Status Score Dynamics in Patients with Relapsing-Remitting Multiple Sclerosis: A Pilot Study.
Int J Mol Sci
December 2024
Department of Infectology, Rīga Stradiņš University, LV-1007 Riga, Latvia.
Forecasting the progression of the disease in the early inflammatory stage of the most prevalent type of multiple sclerosis (MS), referred to as relapsing-remitting multiple sclerosis (RRMS), is essential for making prompt treatment modifications, aimed to reduce clinical relapses and disability. In total, 58 patients with RRMS, having an Expanded Disability Status Scale (EDSS) score less than 4, were included in this study. Baseline magnetic resonance imaging (MRI) was performed, and brain and spinal cord lesions were evaluated.
View Article and Find Full Text PDFCXCL13 levels in cerebrospinal fluid in relapsing-remitting multiple sclerosis: The role of Borrelia in neuroinfections.
J Vector Borne Dis
January 2025
İzmir Tınaztepe University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, İzmir, Türkiye.
Background Objectives: This study was compared the Borrelia antibodies and chemokine ligand 13 (CXCL13) levels in cerebrospinal fluid (CSF) samples from cases diagnosed with relapsing-remitting multiple sclerosis (RRMS), radiologically isolated syndrome (RIS), and pseudotumour cerebri (PTC).
Methods: A total of 43 CSF samples were collected from patients diagnosed with RRMS, RIS and PTC. We prospectively investigated Borrelia IgG and IgM antibodies in the CSF samples of the cases by enzyme-linked immunosorbent assay (ELISA) and Western blot (WB) method, and CXCL13 levels by ELISA.
PANORAMA: A 2021 Clinician Survey of Treatment Approaches for People With New Diagnoses of Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Int J MS Care
January 2025
Novartis Pharmaceuticals UK Ltd, London, United Kingdom.
Background: The PANORAMA survey aimed to assess current treatment practice for individuals with new diagnoses of relapsing-remitting multiple sclerosis (RRMS) in the United Kingdom and to explore variations in treatment approaches with an emphasis on escalation vs early high-efficacy treatment (HET) and treatment goals.
Methods: Health care professionals (HCPs) from the UK treating patients with RRMS took part in interviews facilitated by a structured questionnaire. Data were analyzed descriptively using quantitative or qualitative methods, as appropriate.
[Care and Treatment Guarantee Plan for Patients with Multiple Sclerosis: Impact on Beneficiaries of the Chilean Public System 2008-2018].
Rev Med Chil
July 2024
Servicio de Neurología, Complejo Asistencial Barros Luco Trudeau, Santiago, Chile.
Unlabelled: Multiple sclerosis (MS) is a pathology that mainly affects the young population, causing irreversible disability without treatment. The national multiple sclerosis program improves access to diagnosis, treatment, and prognostic of patients with relapsing-remitting multiple sclerosis (RRMS).
Aim: Describe the biggest cohort of patients with RRMS in the Chilean public health system, analyze the impact of the national program in the clinical evolution and the diagnostic opportunity (time in years between the first outbreak and entry into the program) before and after 2010, date of incorporation of the pathology to the explicit health guarantees program (GES) of the Ministry of Health (MINSAL).
Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile.
Front Immunol
January 2025
Polpharma Biologics S.A., Gdansk, Poland.
Background: Biosimilar natalizumab (biosim-NTZ) is the first biosimilar monoclonal antibody of reference natalizumab (ref-NTZ) for treatment of relapsing forms of multiple sclerosis (MS). Within the totality of evidence for demonstration of biosimilarity, immunogenicity assessments were performed in healthy subjects and patients with relapsing-remitting MS (RRMS) to confirm a matching immunogenicity profile between biosim-NTZ and ref-NTZ.
Methods: Immunogenicity of biosim-NTZ versus ref-NTZ was evaluated in two pivotal clinical studies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!